Continuation Protocol for Obstructive Sleep Apnea (OSA)
Trial details
- Registry ID
- NCT06566820
- Drugs studied
- Aroxybutynin and Atomoxetine
TrialRedline tracks 8 clinical trials sponsored by Apnimed: 3 Phase 3, 5 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Continuation Protocol for Obstructive Sleep Apnea (OSA)NCT06566820 | Aroxybutynin and Atomoxetine | Enrolling by invitation | 2026-06-30Estimated |
| Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)NCT05811247 | AD109 | Completed | 2025-05-07Actual |
| Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)NCT05813275 | AD109 | Completed | 2025-03-10Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study That Tests AD109 in Patients Taking GLP-1 DrugsNCT06400615 | AD109 | Completed | 2024-12-26Actual |
| AD816 Crossover StudyNCT05793684 | Period A, Period B, Period C | Completed | 2023-11-09Actual |
| Trial of AD113 and Atomoxetine in OSA Patients With HypertensionNCT04905979 | AD113, Atomoxetine | Completed | 2023-01-31Actual |
| Parallel Arm Trial of AD109 and AD504 In Patients With OSANCT05071612 | AD109, AD504, Atomoxetine Hydrochloride | Completed | 2022-07-20Actual |
| Crossover Trial of AD036 in Obstructive Sleep ApneaNCT04445688 | AD036, Atomoxetine | Completed | 2020-12-01Actual |
Names as written in the registry records.
NCT05811247 · Apnimed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline in Apnea-Hypopnea Index (AHI) Description: AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%. Time frame: 6 months. After: Measure: Change From Baseline in Apnea-Hypopnea Index (AHI) Description: AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%. Time frame: 6 months.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline in Apnea-Hypopnea Index (AHI). After: Measure: Change From Baseline in Apnea-Hypopnea Index (AHI).
NCT05071612 · Apnimed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in AHI, Combined AD109 Dose Arms vs. Combined Placebo Arms. After: Measure: Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo.
NCT05071612 · Apnimed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in AHI, combined AD109 dose arms vs. combined placebo arms. After: Measure: Change in AHI, Combined AD109 Dose Arms vs. Combined Placebo Arms.